CN111094339A - 抗pd-1抗体和抗lag-3抗体联合在制备治疗肿瘤的药物中的用途 - Google Patents

抗pd-1抗体和抗lag-3抗体联合在制备治疗肿瘤的药物中的用途 Download PDF

Info

Publication number
CN111094339A
CN111094339A CN201880059078.7A CN201880059078A CN111094339A CN 111094339 A CN111094339 A CN 111094339A CN 201880059078 A CN201880059078 A CN 201880059078A CN 111094339 A CN111094339 A CN 111094339A
Authority
CN
China
Prior art keywords
seq
chain variable
variable region
antibody
heavy chain
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
CN201880059078.7A
Other languages
English (en)
Other versions
CN111094339B (zh
Inventor
黄晓辉
曹国庆
杨昌永
张连山
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Jiangsu Hengrui Medicine Co Ltd
Shanghai Hengrui Pharmaceutical Co Ltd
Suzhou Suncadia Biopharmaceuticals Co Ltd
Original Assignee
Jiangsu Hengrui Medicine Co Ltd
Shanghai Hengrui Pharmaceutical Co Ltd
Suzhou Suncadia Biopharmaceuticals Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Jiangsu Hengrui Medicine Co Ltd, Shanghai Hengrui Pharmaceutical Co Ltd, Suzhou Suncadia Biopharmaceuticals Co Ltd filed Critical Jiangsu Hengrui Medicine Co Ltd
Publication of CN111094339A publication Critical patent/CN111094339A/zh
Application granted granted Critical
Publication of CN111094339B publication Critical patent/CN111094339B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Immunology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biochemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

提供一种抗PD‑1抗体和抗LAG‑3抗体联合在制备治疗肿瘤的药物中的用途。具体而言，涉及抗PD‑1抗体或其抗原结合片段和抗LAG‑3抗体或其抗原结合片段联合在制备治疗肿瘤和/或增强T细胞活性的药物中的用途。

Description

PCT国内申请，说明书已公开。

Claims (22)

  1. PCT国内申请，权利要求书已公开。
CN201880059078.7A 2017-10-17 2018-10-16 抗pd-1抗体和抗lag-3抗体联合在制备治疗肿瘤的药物中的用途 Active CN111094339B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CN201710965926 2017-10-17
CN2017109659268 2017-10-17
PCT/CN2018/110324 WO2019076277A1 (zh) 2017-10-17 2018-10-16 抗pd-1抗体和抗lag-3抗体联合在制备治疗肿瘤的药物中的用途

Publications (2)

Publication Number Publication Date
CN111094339A true CN111094339A (zh) 2020-05-01
CN111094339B CN111094339B (zh) 2023-01-24

Family

ID=66174315

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201880059078.7A Active CN111094339B (zh) 2017-10-17 2018-10-16 抗pd-1抗体和抗lag-3抗体联合在制备治疗肿瘤的药物中的用途

Country Status (3)

Country Link
CN (1) CN111094339B (zh)
TW (1) TW201916890A (zh)
WO (1) WO2019076277A1 (zh)

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN113616788A (zh) * 2020-05-08 2021-11-09 勤浩医药（苏州）有限公司 抗lag-3抗体与shp-2抑制剂联合治疗肿瘤的用途
CN115845051A (zh) * 2022-12-28 2023-03-28 广州誉衡生物科技有限公司 一种药物组合物和药物制剂及其在治疗肝癌中的应用
CN115845052A (zh) * 2022-12-28 2023-03-28 广州誉衡生物科技有限公司 一种药物组合物和药物制剂及其在治疗结肠癌中的应用
CN115869399A (zh) * 2022-12-28 2023-03-31 广州誉衡生物科技有限公司 一种药物组合物和药物制剂及其在治疗非小细胞肺癌中的应用

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN114522229B (zh) * 2022-02-25 2023-09-29 南京大学 一种减毒沙门氏菌和pd-1抗体抑制剂联合药物及其在制备治疗肿瘤药物中的应用

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN105793287A (zh) * 2013-09-20 2016-07-20 百时美施贵宝公司 抗lag-3抗体与抗pd-1抗体联合治疗肿瘤

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR072999A1 (es) * 2008-08-11 2010-10-06 Medarex Inc Anticuerpos humanos que se unen al gen 3 de activacion linfocitaria (lag-3) y los usos de estos
BR112012025730B1 (pt) * 2010-04-09 2020-12-08 Aveo Pharmaceuticals, Inc anticorpo isolado que se liga ao erbb3 humano, seus usos, seu processo de produção e vetor de expressão
MX2015012326A (es) * 2013-03-15 2016-03-08 Genentech Inc Anticuerpos anti-crth2 y su uso.
EP3049442A4 (en) * 2013-09-26 2017-06-28 Costim Pharmaceuticals Inc. Methods for treating hematologic cancers
LT3081576T (lt) * 2013-12-12 2019-10-25 Shanghai hengrui pharmaceutical co ltd Pd-1 antikūnas, antigeną surišantis jo fragmentas ir jų medicininis pritaikomumas
CN106999591B (zh) * 2015-09-28 2021-02-23 苏州盛迪亚生物医药有限公司 一种抗pd-1抗体制剂及其在医药上的应用

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN105793287A (zh) * 2013-09-20 2016-07-20 百时美施贵宝公司 抗lag-3抗体与抗pd-1抗体联合治疗肿瘤

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
BUROVA, ELENA等: "Combined treatment with anti-LAG-3 and anti-PD-1 fully human monoclonal antibodies inhibits tumor growth in immunocompetent double humanized LAG-3/PD-1 mice", 《CANCER RESEARCH》 *

Cited By (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN113616788A (zh) * 2020-05-08 2021-11-09 勤浩医药（苏州）有限公司 抗lag-3抗体与shp-2抑制剂联合治疗肿瘤的用途
CN115845051A (zh) * 2022-12-28 2023-03-28 广州誉衡生物科技有限公司 一种药物组合物和药物制剂及其在治疗肝癌中的应用
CN115845052A (zh) * 2022-12-28 2023-03-28 广州誉衡生物科技有限公司 一种药物组合物和药物制剂及其在治疗结肠癌中的应用
CN115869399A (zh) * 2022-12-28 2023-03-31 广州誉衡生物科技有限公司 一种药物组合物和药物制剂及其在治疗非小细胞肺癌中的应用
CN115845052B (zh) * 2022-12-28 2023-12-29 广州誉衡生物科技有限公司 一种药物组合物和药物制剂及其在治疗结肠癌中的应用
CN115869399B (zh) * 2022-12-28 2024-01-12 广州誉衡生物科技有限公司 一种药物组合物和药物制剂及其在治疗非小细胞肺癌中的应用
CN115845051B (zh) * 2022-12-28 2024-02-02 广州誉衡生物科技有限公司 一种药物组合物和药物制剂及其在治疗肝癌中的应用

Also Published As

Publication number Publication date
CN111094339B (zh) 2023-01-24
WO2019076277A1 (zh) 2019-04-25
TW201916890A (zh) 2019-05-01

Similar Documents

Publication Publication Date Title
US11981733B2 (en) LAG-3 antibody, antigen-binding fragment thereof, and pharmaceutical application thereof
CN110050000B (zh) 含有TGF-β受体的融合蛋白及其医药用途
US11365255B2 (en) PD-1 antibody, antigen-binding fragment thereof, and medical application thereof
CN107151269B (zh) 一种pdl-1抗体、其药物组合物及其用途
CN108779180B (zh) 新型抗-pd-l1抗体
CN111094339B (zh) 抗pd-1抗体和抗lag-3抗体联合在制备治疗肿瘤的药物中的用途
CN112969716B (zh) 抗pd-1抗体、其抗原结合片段及医药用途
CN110790839B (zh) 抗pd-1抗体、其抗原结合片段及医药用途
WO2021115303A1 (zh) 一种抗Claudin18.2单克隆抗体、其制备方法及用途
JP2023500156A (ja) 抗－ヒトプログラム細胞死リガンド－１（ｐｄ－ｌ１）の抗体及びその用途
TWI843799B (zh) 抗pd-1抗體、其抗原結合片段及醫藥用途
WO2022247826A1 (zh) 靶向pd-l1和cd73的特异性结合蛋白
TWI833227B (zh) 靶向pd-l1和cd73的特異性結合蛋白及其應用

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant